Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Huang

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Molecular Cancer Therapeutics|March 1, 2015
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor EverolimusHung Huynh, Huai-Xiang Hao, Stephen L Chan, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2007
Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3Michael Johnson, An-Rong Li, Jiwen Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyDejan Juric, Jordi Rodon, Josep Tabernero, et al.
Journal of Medicinal Chemistry|April 10, 2024
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted CancersKevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitorScott Throner, Tianshu Feng, Jannik N Andersen, et al.
Cancer Cell|July 9, 2014
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitorsSadhna R Vora, Dejan Juric, Nayoon Kim, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Molecular Cancer Therapeutics|May 6, 2025
CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumorsKatherine Lazarides, Justin L Engel, Michele Meseonznik, et al.
Cell Reports Methods|June 1, 2026
Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screensSilvia Fenoglio, Yi Yu, James Tepper, et al.
Molecular Cancer Therapeutics|January 27, 2025
LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant CancersLauren Catherine M Martires, Leanne G Ahronian, Charlotte B Pratt, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Molecular Cancer Therapeutics|March 1, 2015
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor EverolimusHung Huynh, Huai-Xiang Hao, Stephen L Chan, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2007
Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3Michael Johnson, An-Rong Li, Jiwen Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyDejan Juric, Jordi Rodon, Josep Tabernero, et al.
Journal of Medicinal Chemistry|April 10, 2024
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted CancersKevin M Cottrell, Kimberly J Briggs, Douglas A Whittington, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2025
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitorScott Throner, Tianshu Feng, Jannik N Andersen, et al.
Cancer Cell|July 9, 2014
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitorsSadhna R Vora, Dejan Juric, Nayoon Kim, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Molecular Cancer Therapeutics|May 6, 2025
CRISPR screens identify POLB as a synthetic lethal enhancer of PARP inhibition exclusively in BRCA-mutated tumorsKatherine Lazarides, Justin L Engel, Michele Meseonznik, et al.
Cell Reports Methods|June 1, 2026
Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screensSilvia Fenoglio, Yi Yu, James Tepper, et al.
Molecular Cancer Therapeutics|January 27, 2025
LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant CancersLauren Catherine M Martires, Leanne G Ahronian, Charlotte B Pratt, et al.
Pageof 8